CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

John Mendelsohn, Marie Prewett, Patricia Rockwell, Neil I Goldstein

Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Jan 15

filter terms:

Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval. ©2015 American Association for Cancer Research.

Citation

John Mendelsohn, Marie Prewett, Patricia Rockwell, Neil I Goldstein. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 15;21(2):227-9